BioRegenx Statistics
Total Valuation
BioRegenx has a market cap or net worth of 13.47 million. The enterprise value is 15.68 million.
| Market Cap | 13.47M |
| Enterprise Value | 15.68M |
Important Dates
The next estimated earnings date is Monday, April 13, 2026.
| Earnings Date | Apr 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioRegenx has 961.99 million shares outstanding. The number of shares has increased by 10.50% in one year.
| Current Share Class | 961.99M |
| Shares Outstanding | 961.99M |
| Shares Change (YoY) | +10.50% |
| Shares Change (QoQ) | +0.17% |
| Owned by Insiders (%) | 12.46% |
| Owned by Institutions (%) | n/a |
| Float | 248.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.98 |
| PB Ratio | -3.69 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.83 |
| EV / Sales | 8.12 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -326.40 |
Financial Position
The company has a current ratio of 0.07
| Current Ratio | 0.07 |
| Quick Ratio | 0.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -46.95 |
| Interest Coverage | -8.01 |
Financial Efficiency
Return on equity (ROE) is -381.82% and return on invested capital (ROIC) is -21.06%.
| Return on Equity (ROE) | -381.82% |
| Return on Assets (ROA) | -16.28% |
| Return on Invested Capital (ROIC) | -21.06% |
| Return on Capital Employed (ROCE) | 87.22% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 385,872 |
| Profits Per Employee | -3.79M |
| Employee Count | 5 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 2.70 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +14.29% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +14.29% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 48.51 |
| Average Volume (20 Days) | 67,583 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.14 |
Income Statement
In the last 12 months, BioRegenx had revenue of 1.93 million and -18.93 million in losses. Loss per share was -0.02.
| Revenue | 1.93M |
| Gross Profit | 1.51M |
| Operating Income | -2.41M |
| Pretax Income | -18.93M |
| Net Income | -18.93M |
| EBITDA | -1.80M |
| EBIT | -2.41M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 46,947 in cash and 2.25 million in debt, with a net cash position of -2.21 million or -0.00 per share.
| Cash & Cash Equivalents | 46,947 |
| Total Debt | 2.25M |
| Net Cash | -2.21M |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -3.65M |
| Book Value Per Share | -0.00 |
| Working Capital | -3.66M |
Cash Flow
In the last 12 months, operating cash flow was -42,025 and capital expenditures -6,000, giving a free cash flow of -48,025.
| Operating Cash Flow | -42,025 |
| Capital Expenditures | -6,000 |
| Free Cash Flow | -48,025 |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | 78.14% |
| Operating Margin | -125.04% |
| Pretax Margin | -980.96% |
| Profit Margin | n/a |
| EBITDA Margin | -93.34% |
| EBIT Margin | -125.04% |
| FCF Margin | n/a |
Dividends & Yields
BioRegenx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.50% |
| Shareholder Yield | -10.50% |
| Earnings Yield | -140.53% |
| FCF Yield | -0.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioRegenx has an Altman Z-Score of -50.57 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -50.57 |
| Piotroski F-Score | 3 |